Genelabs Technologies
Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.
7-day free trial · no credit card
Verified contacts
22
available on Kipplo
LinkedIn employees
51 to 200
headcount range
Open roles
—
no listings
Distinct roles
21
indexed titles
Tech stack
1
tools in use
Monthly traffic
—
organic / mo
Sign up free to see all 22 verified contacts at Genelabs Technologies
Free for 7 days · 50 credits · no card · only pay for verified records.
Decision-makers and verified team members
22 contacts with verified email or phone · masked until revealed.
- LL
Lillian Lou
Project Director · Research & Development
EmailPhone - BB
Barbara Bivens
Sr Manager, Purchasing · Purchasing
EmailPhone - AB
Andrea Berki
Receptionist · General Business & Management
EmailPhone - FD
Fred Driscoll
CEO · General Business & Management
EmailPhone
Showing 4 of 22 verified contacts
Top roles at Genelabs Technologies
21 distinct titles indexed · top 10 shown.
- 1assoc director, intellectual property
- 1ceo
- 1director, corporate services
- 1president
- 1project director
- 1project health safety environment manager
- 1receptionist
- 1receptionist asisstant
- 1research administrative coordinator
- 1research associate ii
- +11more titles
Sign up to unlock all 22 contacts at Genelabs Technologies
Free for 7 days · 50 credits · no card · only pay for verified records.
Sign up to reveal 22 verified contacts at Genelabs Technologies
7-day trial · no credit card · cancel anytime · only pay for verified records.
Trusted by sales, marketing, and GTM engineering teams.